Related Experiment Video
Updated: Aug 4, 2026
16:40
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Implantable cardioverter defibrillators in heart failure
M O Sweeney1, K E Ellison, W G Stevenson
1Cardiac Arrhythmia Service, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. mosweeney@partners.org
Cardiology Clinics
|November 22, 2001
Summary
Implantable cardioverter defibrillators effectively treat ventricular arrhythmias in heart failure patients, reducing sudden cardiac death risk. However, they do not improve overall survival when severe pump dysfunction is the primary concern.
Area of Science:
- Cardiology
- Biomedical Engineering
- Medical Devices
Background:
- Implantable cardioverter defibrillators (ICDs) are crucial for managing life-threatening ventricular arrhythmias.
- Heart failure patients are at increased risk for sudden arrhythmic death.
Purpose of the Study:
- To evaluate the efficacy of ICDs in treating spontaneous ventricular tachycardia (VT) and ventricular fibrillation (VF).
- To assess the impact of ICDs on overall survival in heart failure patients.
- To highlight the importance of patient selection in arrhythmia management.
Main Methods:
- Review of clinical data on ICD implantation and outcomes.
- Analysis of survival rates in heart failure patients with and without ICDs.
- Discussion of current and future ICD functionalities.
Main Results:
- ICDs effectively treat spontaneous VT and VF, reducing arrhythmic death risk.
- ICDs do not improve overall survival in patients with imminent death from severe pump dysfunction.
- Appropriate patient selection is critical for optimizing ICD therapy.
Conclusions:
- ICDs are vital for preventing sudden arrhythmic death in selected heart failure patients.
- Future ICDs aim to address atrial arrhythmias, enhance ventricular function, and monitor hemodynamics.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...